Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases.

CONCLUSION: Myeloablative chemotherapy against leukemia may cause POI. HT may relieve perimenopausal symptoms after myeloablative chemotherapy and HSCT. HT was safe and no excessive recurrences or mortality were seen in the hormone-treated group for patients who survived from malignant hematologic diseases and who received HSCT. PMID: 28399661 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28399661?dopt=Abstract

Source: Climacteric - April 11, 2017 Category: Geriatrics Authors: Yang X, Wang C, He X, Wei J, Wang Y, Li X, Xu LP Tags: Climacteric Source Type: research